Cogent Biosciences, Inc. Retained Earnings
Cogent Biosciences, Inc. (COGT) had Retained Earnings of -$1.38 billion as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.38B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.29B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.19B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.09B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.38B 10-Q · filed 2026-08-10 |
| 2026-03-31 | -$1.29B 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$1.19B 10-Q · filed 2026-08-10 |
| 2025-09-30 | -$1.09B 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$1.00B 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$931.47M 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$859.48M 10-K · filed 2026-02-17 |
| 2024-09-30 | -$791.56M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$720.92M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$661.97M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$603.62M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$549.26M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$493.88M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$449.80M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$411.21M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$371.60M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$336.53M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$301.61M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$270.97M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$246.06M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$226.98M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$210.43M 10-Q · filed 2021-05-12 |
| 2020-12-31 | -$198.70M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$187.36M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$137.38M 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$129.99M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$123.89M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$126.19M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$114.27M 10-Q · filed 2019-08-12 |
| 2019-03-31 | -$103.75M 10-Q · filed 2019-05-13 |
| 2018-12-31 | -$92.06M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$83.45M 10-Q · filed 2018-11-13 |
| 2018-06-30 | -$73.28M 10-Q · filed 2018-08-13 |
| 2018-03-31 | -$64.26M 10-Q · filed 2018-05-14 |
| 2017-12-31 | -$51.34M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |